Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Case Comprehensive Cancer Center Identifier:
First received: May 2, 2000
Last updated: June 9, 2010
Last verified: June 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2003
  Primary Completion Date: April 2002 (Final data collection date for primary outcome measure)
Cooper BW, Ksenich P, Koc O, et al.: A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan (FCT) for relapsed/refractory acute leukemia (RAL) and advanced myelodysplastic syndromes (MDS). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1207, 2001.